Madhumita Premkumar, Kamal Kajal, K Rajender Reddy, Manhal Izzy, Anand V Kulkarni, Ajay Kumar Duseja, K Bhupendra Sihag, Smita Divyaveer, Ankur Gupta, Sunil Taneja, Arka De, Nipun Verma, Sahaj Rathi, Harish Bhujade, Sreedhara B Chaluvashetty, Akash Roy, Vishesh Kumar, Vuppada Siddhartha, Virendra Singh, Ajay Bahl
BACKGROUND AND AIMS: Treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI), with terlipressin and albumin, provides survival benefits, but may be associated with cardiopulmonary complications. We analyzed the predictors of terlipressin response and mortality using point-of-care echocardiography (POC-Echo) and cardiac and renal biomarkers. APPROACH: Between December 2021 and January 2023, patients with HRS-AKI were assessed with POC-Echo and lung ultrasound within 6 hours of admission, at the time of starting terlipressin (48 h), and at 72 hours...
November 16, 2023: Hepatology: Official Journal of the American Association for the Study of Liver Diseases